David Hutton

Procedure provides ophthalmologists with another treatment option.

An action filed in U.S. District Court for the Northern District of Illinois by a Pennsylvania woman alleges that neither she nor her physicians were alerted that Tepezza could result in loss of hearing or tinnitus. Horizon said in a statement this and other lawsuits are without merit.

The Centre for Ocular Research and Education is demonstrating its latest discoveries for eye applications at the Association for Research in Vision and Ophthalmology’s annual meeting in New Orleans.

The company said this week it plans to open the trial for enrollment this quarter and expects topline results by the third quarter of 2024.

The GA Won’t Wait campaign is designed to help older adults and their families understand and recognize the symptoms of this progressive and irreversible disease.

Vance Thompson, MD, sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss his presentation at the Real World Ophthalmology meeting on Pearls for cataract surgery.

The technology could prove to be the foundation for establishing a new biomarker of ocular diseases.

Jennifer Lim, MD, FARVO sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss her presentation at this year's Vit-Buckle Society meeting on keratoprosthesis combined with vitrectomy surgery.

J. Peter Campbell, MD, MPH, sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss pediatric retina surgery and 3 key pearls to consider while performing the surgery.

According to the company, intermediate dry AMD Treatment Is a significant unmet need, with mitochondrial stabilizing candidate risuteganib demonstrating BCVA gains in the dry AMD patient population.

According to the company, KPI-012 could become the first approved treatment for persistent corneal epithelial defect across all its various etiologies.

Esen Akpek, MD, sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss ocular surface disease and the lifestyle choices that could affect eye health. As well as what The Tear Film & Ocular Surface Society is doing to promote research on the topic.

A research team made up of scientists from a trio of European universities and led by a Northumbria University academic, has received funding to research age-related macular degeneration.

If no comment from the FDA is received within 30 days, the company said it will initiate the BRM424 phase 2 study in the first half of 2023.

According to data, 62% of patients treated with teprotumumab-trbw had a clinically meaningful improvement in proptosis at Week 24compared with 25% of patients receiving placebo.

A team of researchers has uncovered a mechanism that causes blindness, could lead to targeted therapies.

According to National Eye Institute researchers, the variants generate malformed proteins that alter the stability of the membrane attack complex, which may drive a chronic inflammatory response in the retina.

Ophthalmologists can learn the latest techniques to help patients like Tommy Pham from the New York Mets during the first annual IKA Keratoconus Symposium: Front to Back and Everything In Between, taking place April 22-23 in Scottsdale, Arizona.

Eyenuk Inc. founder and CEO Kaushal Solanki, PhD, went from working for the Defense Department to founding a company with a focus on artificial intelligence for ophthalmology. Find out what led him to make that jump.

By crossing into the retina, investigators have uncovered a new DHA supplement achieves what previous ones could not.

The company could also consider partnerships or licensing agreements for some drugs of its ophthalmology pipeline, including pegcetacoplan.

According to National Eye Institute researchers, the strategy may speed the delivery of therapeutic options relative to time it would take to develop gene therapies.

According to the company, clinically meaningful visual acuity gains were observed in several MCO-010 treated patients. The trial also demonstrated a favorable safety profile for MCO-010 with no serious or severe adverse events.

Researchers at Buck Institute, working with Google Health and Zuckerberg San Francisco General Hospital, are studying the eye as a window into human aging.

Allergan developed VUITY, which it noted is the first and only FDA-approved eye drop to treat presbyopia. The FDA has now approved a two-dose option.

The Centers for Medicare and Medicaid Services accepted comments on the proposed rule and several organizations, including the American Academy of Ophthalmology, chimed in with comments and offered suggestions.

According to researchers at UCLA, “dormant” cone photoreceptors might continue to drive retinal activity for vision.

The company’s market tracker enables comprehensive brand-level market analysis and direct access to real-world data from the IRIS Registry.

Nitish Mehta, MD discusses the latest trends in Artificial Intelligence and Machine Learning technology in retinal imaging and its uses for ophthalmologists.

The study of UBX1325 is in patients with wet age-related macular degeneration (AMD) who were not achieving optimum benefit with their ongoing anti-VEGF therapy.